Company Description

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.

The company uses its proprietary technology to develop its products comprising Capture and Contain, a containment barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.

It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.

Polyrizon Ltd.

Country	Israel
Founded	2005
IPO Date	Oct 29, 2024
Industry	Biotechnology
Sector	Healthcare
Employees	3
CEO	Tomer Izraeli

Contact Details

Address: 5 Ha-Tidhar Street Ra'anana, 4366507 Israel
Phone	972 5 5433 5665
Website	polyrizon-biotech.com

Stock Details

Ticker Symbol	PLRZ
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$4.38
CIK Code	0001893645
ISIN Number	IL0011814113
SIC Code	2834

Key Executives

Name	Position
Tomer Izraeli	Chief Executive Officer, Director
Nir Ben Yosef	Chief Financial Officer
Dr. Eyal S. Ron	Chief Technology Officer
Dr. Tidhar Turgeman	Chief R&D Officer
Daphna Avital	Chief People Officer
Dr. Roy Borochov	Director
Liron Carmel	Director
Oz Adler	Director
Raul Srugo	Director

Latest SEC Filings

Date	Type	Title
Dec 19, 2024	6-K	Report of foreign issuer
Dec 13, 2024	6-K	Report of foreign issuer
Dec 2, 2024	6-K	Report of foreign issuer
Oct 30, 2024	6-K	Report of foreign issuer
Oct 30, 2024	424B4	Prospectus
Oct 30, 2024	424B4	Prospectus
Oct 28, 2024	EFFECT	Notice of Effectiveness
Oct 28, 2024	CERT	Certification by an exchange approving securities for listing
Oct 21, 2024	8-A12B	Registration of securities
Oct 2, 2024	F-1/A	[Amend] Registration statement for certain foreign private issuers

View All SEC Filings